Holen Sie sich die Stockscreener-App
93.19
3.63%
3.26
Schlusskurs vom Vortag:
$89.93
Offen:
$91.16
24-Stunden-Volumen:
1.24M
Relative Volume:
1.08
Marktkapitalisierung:
$8.22B
Einnahmen:
$688.00K
Nettoeinkommen (Verlust:
$-168.74M
KGV:
-39.53
EPS:
-2.3577
Netto-Cashflow:
$-185.87M
1W Leistung:
+8.75%
1M Leistung:
+7.05%
6M Leistung:
+95.86%
1J Leistung:
+483.17%
1-Tages-Spanne:
$90.48
$95.27
1-Wochen-Bereich:
$83.25
$95.27
52-Wochen-Spanne:
$15.86
$110.17
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Firmenname
Spyre Therapeutics Inc
Sektor
Branche
Telefon
(617) 651-5940
Adresse
221 CRESCENT STREET, WALTHAM
Compare SYRE vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
93.19 | 7.56B | 688.00K | -168.74M | -185.87M | -2.3577 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Eingeleitet | Raymond James | Strong Buy |
| 2025-12-18 | Eingeleitet | Mizuho | Outperform |
| 2025-12-17 | Eingeleitet | Citigroup | Buy |
| 2025-09-26 | Eingeleitet | Deutsche Bank | Buy |
| 2025-04-08 | Eingeleitet | Leerink Partners | Outperform |
| 2025-03-18 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-04 | Eingeleitet | Wedbush | Outperform |
| 2024-07-16 | Eingeleitet | Evercore ISI | Outperform |
| 2024-05-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-03-01 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | Eingeleitet | BTIG Research | Buy |
| 2023-12-11 | Eingeleitet | Guggenheim | Buy |
| 2023-12-11 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2019-03-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-09-04 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-14 | Bestätigt | Needham | Buy |
Alle ansehen
Spyre Therapeutics Inc Aktie (SYRE) Neueste Nachrichten
45,000 shares are proposed for sale at Spyre Therapeutics (SYRE), following two earlier sales. - Stock Titan
A passive investor reports more than 5% ownership of Spyre Therapeutics (SYRE). - Stock Titan
Spyre draws new Overweight at J.P. Morgan on IBD potential - Seeking Alpha
SYRE Initiates Coverage On JP Morgan -- Rating Set to Overweight - GuruFocus
SYRE Reiterated by BTIG -- Price Target Maintained at $121 - GuruFocus
Why is Spyre Therapeutics stock climbing today? By Investing.com - Investing.com Canada
JPMorgan initiates Spyre stock with Overweight on IBD pipeline - Investing.com
Spyre Therapeutics gains as investors continue to digest positive Phase 2 bowel disease data - Quiver Quantitative
A 17,500-share sale is proposed by Spyre Therapeutics (Nasdaq: SYRE) officer Scott Burrows. - Stock Titan
SYRE Stock Steadies As SPY003 Trial Data De-Risks IBD Pipeline - StocksToTrade
SYRE Stock Steadies As SPY003 Data Resets Biotech Expectations - timothysykes.com
Why is Spyre Therapeutics stock rallying today? By Investing.com - Investing.com Canada
Spyre Therapeuticsの社内関係者が保有株を28%削減 - Moomoo
JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $121 - Moomoo
SYRE News | SPYRE THERAPEUTICS INC (NASDAQ:SYRE) - ChartMill
Cameron Turtle: The $1.6 Billion Bet That IBD's 25% Ceiling Is About to Break - finance.biggo.com
Spyre Therapeutics at Stifel forum: betting on autoimmune combinations By Investing.com - Investing.com Canada
Spyre Therapeutics, Inc. (SYRE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Spyre Therapeutics, Inc. (SYRE) stock price, news, quote and history - Yahoo Finance Australia
What Does Spyre Therapeutics (SYRE) Part A Trial Success Mean For Ulcerative Colitis? - Yahoo Finance
Spyre Therapeutics, Inc Income Statement – MUN:3920 - TradingView
Equity in earnings of Spyre Therapeutics, Inc – MUN:3920 - TradingView
Total liabilities of Spyre Therapeutics, Inc – MUN:3920 - TradingView
Price to cash flow ratio of Spyre Therapeutics, Inc – MUN:3920 - TradingView
Spyre Therapeutics, Inc. (SYRE) Investor Outlook: A Biotech Stock with a Potential 29.56% Upside - DirectorsTalk Interviews
Spyre (SYRE) Clears Monotherapy Phase for IBD Portfolio, Setting Up Combination Tests - Yahoo Finance
Spyre Therapeutics, Inc Statistics – GETTEX:3920 - TradingView
Spyre Therapeutics (SYRE) Reports SPY003 Endoscopic Improvement. Can Randomized Testing Confirm It? - Yahoo Finance
Spyre Therapeutics at Wells Fargo conference: betting on combination biologics - Investing.com Canada
Transcript : Spyre Therapeutics, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 10 - marketscreener.com
Spyre Therapeutics at Citi summit: bets on autoimmune combinations By Investing.com - Investing.com Canada
Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study - The Globe and Mail
Spyre Therapeutics Inc at Citi Biopharma Back to School Summit Transcript - GuruFocus
Guggenheim Reveals Top Biotech Stock After Positive Clinical Trial Data By Investing.com - Investing.com South Africa
SYRE Reiterated by Wedbush -- Maintained Price Target at $123 - GuruFocus
Baird reiterates Spyre stock Outperform rating on positive trial data By Investing.com - Investing.com India
Spyre Therapeutics (SYRE) Reports Positive Phase 2 SKYLINE Trial Results Amid High Valuation Concerns - GuruFocus
Spyre reports positive ulcerative colitis trial data for SPY003 By Investing.com - Investing.com Canada
Spyre reports positive ulcerative colitis trial data for SPY003 - Investing.com
An experimental ulcerative colitis treatment cut a disease score by 10 points - Stock Titan
Spyre posts positive Phase 2 SKYLINE Part A: SPY003 cuts RHI 10.0 pts; Part B enrolling, topline in 2027 - TradingView
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations - Yahoo Finance
SYRE Stock Marks Best Session In About 3 Years — Here’s Why - Stocktwits
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Spyre Therapeutics Insider Sold Shares Worth $1,309,410, According to a Recent SEC Filing - marketscreener.com
Spyre Therapeutics to Participate in Upcoming September Investor Conferences - The Manila Times
Spyre Therapeutics officer Heidy King-Jones sells $2.48m in shares By Investing.com - Investing.com South Africa
Spyre Therapeutics (SYRE) CEO Cameron Turtle Sells 15,000 Shares - GuruFocus
Spyre Therapeutics CFO Scott Burrows sells $2.28m in shares By Investing.com - Investing.com Nigeria
Spyre Therapeutics CEO Cameron Turtle sells $1.3m in shares - investing.com
Spyre Therapeutics officer Heidy King-Jones sells $2.48m in shares - investing.com
Finanzdaten der Spyre Therapeutics Inc-Aktie (SYRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Spyre Therapeutics Inc-Aktie (SYRE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| King-Jones Heidy | See Remarks |
Oct 01 '26 |
Sale |
91.03 |
28,933 |
2,633,902 |
2,845 |
| Turtle Cameron | Chief Executive Officer |
Oct 01 '26 |
Sale |
92.01 |
15,000 |
1,380,105 |
537,540 |
| Burrows Scott L | Chief Financial Officer |
Sep 30 '26 |
Option Exercise |
14.50 |
17,500 |
253,750 |
97,262 |
| Burrows Scott L | Chief Financial Officer |
Oct 01 '26 |
Option Exercise |
14.50 |
7,500 |
108,750 |
87,262 |
| Burrows Scott L | Chief Financial Officer |
Sep 30 '26 |
Sale |
89.89 |
17,500 |
1,573,075 |
79,762 |
| Burrows Scott L | Chief Financial Officer |
Oct 01 '26 |
Sale |
91.83 |
7,500 |
688,756 |
79,762 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):